Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

doi 10.36469/9808

Full Text

Abstract

Available in

Date

Authors

Publisher

Columbia Data Analytics

Related search

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine
Medicine
2012English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

BMC Nephrology
Nephrology
2015English

PCN114 Cost Effectiveness of Adjuvant Cyclophosphamide in the Treatment of Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost-Effectiveness of Dialectical Behaviour Therapy vs. Enhanced Usual Care in the Treatment of Adolescents With Self-Harm

Child and Adolescent Psychiatry and Mental Health
PsychiatryChild HealthMental HealthPediatricsPerinatology
2018English

Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

PMH33 the Cost-Effectiveness of Paliperidone ER in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy